• Citer

Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial

par Eggermont, Alexander A.M.M.;Rutkowski, Piotr;Dutriaux, Caroline;Hofman-Wellenhof, Rainer;Dziewulski, Peter;Marples, Maria;Grange, Floren;Lok, Catherine;Pennachioli, Elisabetta;Robert, Caroline;van Akkooi, Alexander A.C.J.;Bastholt, Lars;Minisini, Alessandro Marco;Marshall, Ernest;Sales, François ;Grob, Jean Jacques;Bechter, Oliver;Schadendorf, Dirk;Marreaud, Sandrine;Kicinski, Michal;Suciu, Stefan ;Testori, Alessandro
Référence European journal of cancer, 133, page (94-103)
Publication Publié, 2020-07

Article révisé par les pairs

• Détails
• Contenu

Titre:	Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial
Auteur:	Eggermont, Alexander A.M.M.; Rutkowski, Piotr; Dutriaux, Caroline; Hofman-Wellenhof, Rainer; Dziewulski, Peter; Marples, Maria; Grange, Floren; Lok, Catherine; Pennachioli, Elisabetta; Robert, Caroline; van Akkooi, Alexander A.C.J.; Bastholt, Lars; Minisini, Alessandro Marco; Marshall, Ernest; Sales, François; Grob, Jean Jacques; Bechter, Oliver; Schadendorf, Dirk; Marreaud, Sandrine; Kicinski, Michal; Suciu, Stefan; Testori, Alessandro
Informations sur la publication:	European journal of cancer, 133, page (94-103)
Statut de publication:	Publié, 2020-07
Sujet CREF:	Cancérologie
Mots-clés:	Adjuvant therapy
	Pegylated interferon
	Randomized trial
	Stage II
	Ulcerated melanoma
Note générale:	SCOPUS: ar.j
	DecretOANoAutActif
Langue:	Anglais
Identificateurs:	urn:issn:0959-8049
	info:doi/10.1016/j.ejca.2020.04.015
	info:pii/S0959804920301817
	info:scp/85085355184
	info:pmid/32470710